Anteris Technologies Global Corp (ASX: AVR) will grow by more than 50% in value after the company closed off a huge capital raise and welcomed a new strategic investor.
Anteris said in a statement to the ASX on Friday that it had raised US$320 million through the issue of new shares at US$5.75 per share.
The raise will bolster the company’s size by more than 60%, with the $467 million raise in Australian dollar terms larger than its ASX value of $370 million and its NASDAQ listing of $394 million.
Key partner on board
Of this new raise, US$90 million was stumped up by Medtronic Plc (NASDAQ: MDT), which Anteris said was the world’s largest medical technology company.
The smaller company said in its statement:
Anteris and Medtronic are aligned around the belief that reshaping the Transcatheter Aortic Valve Replacement (TAVR) market requires advancing clinical science and valve design while maintaining rigorous standards for durability, hemodynamics, and longâterm patient outcomes.
Anteris Chief Executive Officer Wayne Paterson said the investment from Medtronic and other investors was a strong vote of support for the company’s plans.
This strategic investment, along with our underwritten offering of common stock, represent an important milestone for our company. It also provides strong validation of our program from the capital markets and a major strategic innovator. The investment is one aspect of a collaboration that may expand into other strategic areas in the future. Anteris has developed a clinically important, evidence-supported product designed to improve the lives of patients with aortic stenosis as we advance toward regulatory approval.
Clinical trial now well-funded
The funds raised will help Anteris complete the Paradigm clinical trial, which is evaluating the company’s DurAVR THV System in comparison to commercially available transcatheter aortic valve replacement (TAVR) devices in patients with severe aortic stenosis.
Medtronic Vice President Jorie Sokin said Anteris was a recognised pioneer in the TAVR sector.
He added:
Our investment in differentiated innovation like the DurAVR THV technology â which has the potential to offer improved valve performance in a balloon-expandable platform â is core to our commitment to define and drive the future of TAVR, meeting the needs of more aortic stenosis patients and heart teams with a comprehensive portfolio.
While it was founded in Australia, Anteris said it also has a significant presence in Minneapolis, and “is a science driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients”.
Anteris shares were 5.5% higher in early trade at $9.40.
The post Heart tech firm’s shares surge after huge capital raise appeared first on The Motley Fool Australia.
Should you invest $1,000 in Anteris Technologies Ltd right now?
Before you buy Anteris Technologies Ltd shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Anteris Technologies Ltd wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 Jan 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
Leave a Reply